Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02953457
Title Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Roswell Park Cancer Institute Buffalo New York 14263 United States Details
The Feinstein Institute for Medical Research/Lennox Hill Hospital New York New York 10075 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field